Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database

por Bagegni, Nusayba A., Tao, Yu, Ademuyiwa, Foluso O.
Publicado 2019

Neoadjuvant Therapy in Operable Breast Cancer: Application to Triple Negative Breast Cancer

por Ademuyiwa, Foluso O., Ellis, Matthew J., Ma, Cynthia X.
Publicado 2013

Managing breast cancer in younger women: challenges and solutions

por Ademuyiwa, Foluso O, Cyr, Amy, Ivanovich, Jennifer, Thomas, Maria A
Publicado 2015

Associations of race and ethnicity with risk of developing invasive breast cancer after lobular carcinoma in situ

por Dania, Vanessa, Liu, Ying, Ademuyiwa, Foluso, Weber, Jason D., Colditz, Graham A.
Publicado 2019

Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab

por Bagegni, Nusayba A, Davis, Andrew A, Clifton, Katherine K, Ademuyiwa, Foluso O
Publicado 2022

Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer

por Roy, Sudipta, Whitehead, Timothy D., Li, Shunqiang, Ademuyiwa, Foluso O., Wahl, Richard L., Dehdashti, Farrokh, Shoghi, Kooresh I.
Publicado 2021

Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer

por Roy, Sudipta, Whitehead, Timothy D., Li, Shunqiang, Ademuyiwa, Foluso O., Wahl, Richard L., Dehdashti, Farrokh, Shoghi, Kooresh I.
Publicado 2021

Optimal co-clinical radiomics: Sensitivity of radiomic features to tumour volume, image noise and resolution in co-clinical T1-weighted and T2-weighted magnetic resonance imaging

por Roy, Sudipta, Whitehead, Timothy D., Quirk, James D., Salter, Amber, Ademuyiwa, Foluso O., Li, Shunqiang, An, Hongyu, Shoghi, Kooresh I.
Publicado 2020

Impact of the COVID‐19 pandemic on breast, colorectal, lung, and prostate cancer stage at diagnosis according to race

por Berrian, Jennifer, Liu, Ying, Ezenwajiaku, Nkiruka, Moreno‐Aspitia, Alvaro, Holton, Sara J., Toriola, Adetunji T., Colditz, Graham A., Housten, Ashley J., Hall, Lannis, Fiala, Mark A., Ademuyiwa, Foluso O.
Publicado 2022

Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins

por Wang, Junkai, Saltzman, Alexander B., Jaehnig, Eric J., Lei, Jonathan T., Malovannaya, Anna, Holt, Matthew V., Young, Meggie N., Rimawi, Mothaffar F., Ademuyiwa, Foluso O., Anurag, Meenakshi, Kim, Beom-Jun, Ellis, Matthew J.
Publicado 2023

NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer

por Ademuyiwa, Foluso O., Bshara, Wiam, Attwood, Kristopher, Morrison, Carl, Edge, Stephen B., Ambrosone, Christine B., O’Connor, Tracey L., Levine, Ellis G., Miliotto, Anthony, Ritter, Erika, Ritter, Gerd, Gnjatic, Sacha, Odunsi, Kunle
Publicado 2012

Correction: NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer

por Ademuyiwa, Foluso O., Bshara, Wiam, Attwood, Kristopher, Morrison, Carl, Edge, Stephen B., Ambrosone, Christine B., O’Connor, Tracey L., Levine, Ellis G., Miliotto, Anthony, Ritter, Erika, Ritter, Gerd, Gnjatic, Sacha, Odunsi, Kunle
Publicado 2012

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy

por Rizvi, Naiyer, Ademuyiwa, Foluso O, Cao, Z Alexander, Chen, Helen X, Ferris, Robert L, Goldberg, Sarah B, Hellmann, Matthew D, Mehra, Ranee, Rhee, Ina, Park, Jong Chul, Kluger, Harriet, Tawbi, Hussein, Sullivan, Ryan J
Publicado 2023

Personalized ctDNA micro-panels can monitor and predict clinical outcomes for patients with triple-negative breast cancer

por Barnell, Erica K., Fisk, Bryan, Skidmore, Zachary L., Cotto, Kelsy C., Basu, Anamika, Anand, Aparna, Richters, Megan M., Luo, Jingqin, Fronick, Catrina, Anurag, Meenakshi, Fulton, Robert, Ellis, Matthew J., Griffith, Obi L., Griffith, Malachi, Ademuyiwa, Foluso O.
Publicado 2022

A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis

por Krishnamurthy, Jairam, Luo, Jingqin, Suresh, Rama, Ademuyiwa, Foluso, Rigden, Caron, Rearden, Timothy, Clifton, Katherine, Weilbaecher, Katherine, Frith, Ashley, Roshal, Anna, Tandra, Pavan K., Cherian, Mathew, Summa, Tracy, Haas, Brittney, Thomas, Shana, Hernandez-Aya, Leonel, Bergqvist, Mattias, Peterson, Lindsey, Ma, Cynthia X.
Publicado 2022

Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study

por Yao, Song, Zirpoli, Gary, Bovbjerg, Dana H, Jandorf, Lina, Hong, Chi Chen, Zhao, Hua, Sucheston, Lara E, Tang, Li, Roberts, Michelle, Ciupak, Gregory, Davis, Warren, Hwang, Helena, Johnson, Candace S, Trump, Donald L, McCann, Susan E, Ademuyiwa, Foluso, Pawlish, Karen S, Bandera, Elisa V, Ambrosone, Christine B
Publicado 2012

A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)

por Ademuyiwa, Foluso O., Northfelt, Donald W., O’Connor, Tracey, Levine, Ellis, Luo, Jingqin, Tao, Yu, Hoog, Jeremy, Laury, Marie L., Summa, Tracy, Hammerschmidt, Trish, Guo, Zhanfang, Frith, Ashley, Weilbaecher, Katherine, Opyrchal, Mateusz, Aft, Rebecca, Clifton, Katherine, Suresh, Rama, Bagegni, Nusayba, Hagemann, Ian S., Iglesia, Michael D., Ma, Cynthia X.
Publicado 2023

Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer

por Davis, Andrew A., Gerratana, Lorenzo, Clifton, Katherine, Medford, Arielle J., Velimirovic, Marko, Hensing, Whitney L., Bucheit, Leslie, Shah, Ami N., D'Amico, Paolo, Reduzzi, Carolina, Zhang, Qiang, Dai, Charles S., Denault, Elyssa N., Bagegni, Nusayba A., Opyrchal, Mateusz, Ademuyiwa, Foluso O., Bose, Ron, Gradishar, William J., Behdad, Amir, Ma, Cynthia X., Bardia, Aditya, Cristofanilli, Massimo
Publicado 2022

Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer

por Davis, Andrew A., Luo, Jingqin, Zheng, Tiantian, Dai, Chao, Dong, Xiaoxi, Tan, Lu, Suresh, Rama, Ademuyiwa, Foluso O., Rigden, Caron, Rearden, Timothy P., Clifton, Katherine, Weilbaecher, Katherine, Frith, Ashley, Tandra, Pavan K., Summa, Tracy, Haas, Brittney, Thomas, Shana, Hernandez-Aya, Leonel F., Peterson, Lindsay L., Wang, Xiaohong, Luo, Shujun J., Zhou, Kemin, Du, Pan, Jia, Shidong, King, Bonnie L., Krishnamurthy, Jairam, Ma, Cynthia X.
Publicado 2023

A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013

por Ademuyiwa, Foluso O., Gao, Feng, Street, Cherease R., Chen, Ina, Northfelt, Donald W., Wesolowski, Robert, Arora, Mili, Brufsky, Adam, Dees, E. Claire, Santa-Maria, Cesar A., Connolly, Roisin M., Force, Jeremy, Moreno-Aspitia, Alvaro, Herndon, John M., Carmody, Madelyn, Davies, Sherri R., Larson, Sarah, Pfaff, Kathleen L., Jones, Stephanie M., Weirather, Jason L., Giobbie-Hurder, Anita, Rodig, Scott J., Liu, Zheng, Hagemann, Ian S., Sharon, Elad, Gillanders, William E.
Publicado 2022